VERSATOPE THERAPEUTICS, INC.
Lexington, MA · Biotech · Private
Recombinant outer membrane vesicle (rOMV) vaccine expressing conserved influenza antigens, produced in engineered E. coli
- Grants
- $4.0M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Universal Influenza Vaccine | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Multivalent influenza vaccine using recombinant outer membrane vesicles | $224,974 | |
| Federal grant | Department of Health and Human Services · Phase I · Multivalent influenza vaccine using exosomes from probiotic E. coli | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel C. Difficile Vaccine Using Nano-vesicle Delivery System | $299,928 | |
| Federal grant | Department of Health and Human Services · Phase II · Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | $999,762 | |
| Federal grant | Department of Health and Human Services · Phase II · Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | $999,993 | |
| Federal grant | Department of Health and Human Services · Phase II · Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | $999,925 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1122 | Sana Biotechnology | — | $867M |
| 1123 | Walden Biosciences | — | — |
| 1124 | Kriya Therapeutics | — | $769M |
| 1125 | VERSATOPE THERAPEUTICS, INC. | — | — |
| 1126 | Inhibrx, Inc. | — | $669M |
| 1127 | Odyssey Therapeutics | — | $571M |
| 1128 | Moderna | — | $556M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Membrane Vesicles Comprising Multiple Influenza Antigens For Vaccinesapplication
- Membrane Vesicles Comprising Multiple Influenza Antigens For Vaccinesapplication
- Membrane Vesicles Comprising Multiple Influenza Antigens For Vaccinesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.